NEPT Neptune Wellness Solutions Inc

Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB) reports today its consolidated financial results for the three- and six-month periods ended August 31, 2012.

Six month ended August 31, 2012 Financial Results

Nutraceutical Business Results

• Nutraceutical revenues increased by 62% to $14,001,000, for the six-month period ended August 31, 2012, up from $8,636,000 achieved during the corresponding period ended August 31, 2011.
• EBITDA from nutraceutical business for the six-month period ended August 31, 2012 increased by 26% to $1,793,000, up from $1,424,000 obtained during the corresponding period ended August 31, 2011.
• Net loss from nutraceutical business reached $2,749,000 for the six-month period ended August 31, 2012, compared to a net income of $136,000 for the corresponding period ended August 31, 2011.

Consolidated Results

• Revenues increased by 65% to $14,252,000 for the six-month period ended August 31, 2012, up from $8,636,000 achieved during the corresponding period ended August 31, 2011.
• Consolidated EBITDA for the six-month period ended August 31, 2012 was ($562,000), compared to ($1,076,000) obtained during the corresponding period ended August 31, 2011.
• Earnings for the six-month period ended August 31, 2012 resulted into a net loss of ($6,379,000) compared to a net loss of ($3,026,000), for the corresponding period ended August 31, 2011.

"The good progression of our stock price during Q2 2013 had its good and bad sides. Our stock price increased by approximately 20%, which had a direct impact on our stock-based compensation expenses. Because of IFRS standards, stock-option granted to consultants have to be reevaluated every quarter, impacting directly the bottom line. This is a blessing in disguise, because stock price appreciation benefits everyone," said Frédéric Harland, Director Finance.

"Neptune had a strong and record-breaking fiscal year 2012 and the momentum has kept on in the first and second quarter of fiscal 2013," said André Godin, CFO. "Our aggressive policy of volume discount combined with some product reprocessing has contributed to slightly reduce our gross margin percentage for this quarter. This one-time approach has still produced an overall increase in the gross margin in dollar and was mainly put in place to secure market share," he added.

Three month ended August 31, 2012 Financial Results

Nutraceutical Business Results

• Nutraceutical revenues increased by 81% to $7,862,000, for the three-month period ended August 31, 2012, up from $4,353,000 achieved during the corresponding period ended August 31, 2011.
• EBITDA from nutraceutical business for the three-month period ended August 31, 2012 decreased by 22% to $504,000, down from $650,000 obtained during the corresponding period ended August 31, 2011.
• Net loss from nutraceutical business reached $2,797,000 for the three-month period ended August 31, 2012, compared to a net income of $206,000 for the corresponding period ended August 31, 2011.

Consolidated Results

• Revenues increased by 86% to $8,099,000 for the three-month period ended August 31, 2012, up from $4,353,000 achieved during the corresponding period ended August 31, 2011.
• Consolidated EBITDA for the three-month period ended August 31, 2012 was ($704,000), compared to ($908,000) obtained during the corresponding period ended August 31, 2011.
• Earnings for the three-month period ended August 31, 2012 resulted into a net loss of ($4,684,000) compared to a net loss of ($1,768,000), for the corresponding period ended August 31, 2011.

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         +1.450.687.2262
         a.godin@neptunebiotech.com
         www.neptunebiotech.com
         
         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
         dave@howardgroupinc.com
         www.howardgroupinc.com